Found: 13
Select item for more details and to access through your institution.
Mitochondrial-Targeted Antioxidant Peptide SS31 Prevents RPE Cell Death under Oxidative Stress.
- Published in:
- BioMed Research International, 2022, p. 1, doi. 10.1155/2022/6180349
- By:
- Publication type:
- Article
Modified Trabeculectomy versus Glaucoma Drainage Implant Surgery: A Retrospective Comparative Study for Refractory Glaucoma Treatment.
- Published in:
- Oxidative Medicine & Cellular Longevity, 2022, p. 1, doi. 10.1155/2022/3050007
- By:
- Publication type:
- Article
Perioperative Management and Long-Term Outcomes in Ocular Cicatricial Pemphigoid Patients Undergoing Cataract Surgery.
- Published in:
- Oxidative Medicine & Cellular Longevity, 2022, p. 1, doi. 10.1155/2022/2496649
- By:
- Publication type:
- Article
Terbinafine Induced Acute Generalized Exanthematous Pustulosis Treated with Adalimumab: Recalcitrant to Systemic Corticosteroid Therapy.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
SAPHO Syndrome with Palmoplantar Pustulosis as the First Manifestation Successfully Treated with Adalimumab.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
- Published in:
- Scientific Reports, 2016, p. 18517, doi. 10.1038/srep18517
- By:
- Publication type:
- Article
NormaCurve: A SuperCurve-Based Method That Simultaneously Quantifies and Normalizes Reverse Phase Protein Array Data.
- Published in:
- PLoS ONE, 2012, v. 7, n. 6, p. 1, doi. 10.1371/journal.pone.0038686
- By:
- Publication type:
- Article
Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262543
- By:
- Publication type:
- Article
Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262543
- By:
- Publication type:
- Article
Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262543
- By:
- Publication type:
- Article
Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262543
- By:
- Publication type:
- Article
Synthesis, Characterization, and Specific Localization of Mitochondrial-Targeted Antioxidant Peptide SS31 Probe.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/9915699
- By:
- Publication type:
- Article
Efficacy and safety of <sup>177</sup>Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 10, p. 3529, doi. 10.1007/s00259-022-05771-3
- By:
- Publication type:
- Article